{
    "nct_id": "NCT04831944",
    "official_title": "A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment",
    "inclusion_criteria": "* Participants with hepatic impairment.\n* Participants eligible for Group 4 should be in good health.\n* Participants eligible for Groups 1 through 3 may have medical findings consistent with their degree of hepatic dysfunction.\n* Participants with abnormal findings considered not clinically significant by the investigator are eligible.\n* Body mass index within the range of 18.0 to 40.0 kg/m2 (inclusive) at screening.\n* Willingness to avoid pregnancy or fathering children.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Evidence of rapidly deteriorating hepatic function.\n* Participants with serum calcium and phosphorus levels over the upper limits of the institutional normal ranges.\n* History or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study, including any of the following:\n* Participants who have a current, functioning organ transplant or have a scheduled organ transplant in the next 6 weeks from check-in.\n* History of malignancy within 5 years of screening, with the exception of cured basal cell carcinoma, squamous cell carcinoma of the skin, ductal carcinoma in situ, or Gleason 6 prostate cancer.\n* History of clinically significant gastrointestinal disease or surgery (cholecystectomy and appendectomy are allowed) that could impact the absorption of study drug.\n* Participants with severe ascites or an encephalopathy â‰¥ Grade 2.\n* Any major surgery within 4 weeks of screening.\n* Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).\n* Blood transfusion within 4 weeks of check-in. Current or recent history (within 30 days before screening) of a clinically significant bacterial, fungal, parasitic, or mycobacterial infection, or currently receiving systemic antibiotics. Current clinically significant viral infection at screening or check-in.\n* Positive serology for hepatitis B virus (eg, hepatitis B surface antigen) or human immunodeficiency virus. Participants whose results are compatible with immunity due to infection or prior immunization for hepatitis B may be included at the discretion of the investigator.\n* History of alcoholism within 3 months of screening.\n* Positive breath test for ethanol or positive urine screen for drugs of abuse that is not otherwise explained by permitted concomitant medications.\n* Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with another investigational medication or current enrollment in another investigational drug protocol.\n* Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) of study drug administration with strong or moderate inducer or potent inhibitor of CYP3A4.\n* Receipt of live (including attenuated) vaccines or anticipation of need for such a vaccine during the study. (Note: Non-live or inactivated vaccines allowed up to 2 weeks before first dose administration.)\n* Known hypersensitivity or severe reaction to parsaclisib or excipients of parsaclisib.\n* History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator. Inability to be venipunctured or tolerate venous access.\n* Participants eligible for Group 4 who have a history or presence of liver disease or liver injury as indicated by an abnormal clinically significant liver function profile at screening or check-in.\n* Participants eligible for Group 4 who have a positive test for hepatitis C virus.\n* Participants eligible for Group 4 who used tobacco- or nicotine-containing products within 6 months of screening.\n* Women who are pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}